Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review

Pondé, Noam; Aftimos, Philippe; Piccart, Martine

doi:10.1007/s11864-019-0633-6

Cited by 66 publications

(48 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most primary breast tumors respond to initial treatments, but develop resistance months after initial response [ 129 , 130 ]. To overcome this resistance, exosomal miRNAs and exosomes transporting other molecular cargo have been explored as second-line treatments for refractory breast cancer in light of their essential role in tumor drug resistance ( Table 2 ) [ 131 ].…”

Section: Exosomal Micrornas As Cancer Therapeuticsmentioning

confidence: 99%

Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis

Wong

Jalboush

2020

Cancers

View full text Add to dashboard Cite

Breast cancer is the most frequent malignancy for women in which one in eight women will be diagnosed with the disease in their lifetime. Despite advances made in treating primary breast cancer, there is still no effective treatment for metastatic breast cancer. Consequently, metastatic breast cancer is responsible for 90% of breast cancer-related deaths while only accounting for approximately one third of all breast cancer cases. To help develop effective treatments for metastatic breast cancer, it is important to gain a deeper understanding of the mechanisms by which breast cancer metastasizes, particularly, those underlying organotropism towards brain, bone, and lungs. In this review, we will primarily focus on the roles that circulating exosomal microRNAs (miRNAs) play in organotropism of breast cancer metastasis. Exosomes are extracellular vesicles that play critical roles in intercellular communication. MicroRNAs can be encapsulated in exosomes; cargo-loaded exosomes can be secreted by tumor cells into the tumor microenvironment to facilitate tumor–stroma interactions or released to circulation to prime distant organs for subsequent metastasis. Here, we will summarize our current knowledge on the biogenesis of exosomes and miRNAs, mechanisms of cargo sorting into exosomes, the exosomal miRNAs implicated in breast cancer metastasis, and therapeutic exosomal miRNAs.

show abstract

Section: Exosomal Micrornas As Cancer Therapeuticsmentioning

confidence: 99%

Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis

Wong

Jalboush

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Immunotherapy using therapeutic antibodies, which have blocking activity between a receptor and ligand, or antibody-dependent cellular cytotoxic (ADCC) activity, have become the predominant class of new drugs developed in recent years for various tumors [ 22 , 23 , 24 , 25 , 26 , 27 ]. Recently, PDPN has attracted attention as a novel target antigen for the development of antibody therapy because PDPN is expressed on various refractory tumors.…”

Section: Introductionmentioning

confidence: 99%

Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma

Kamoto

Shinada

Kato

et al. 2020

Cells

View full text Add to dashboard Cite

Podoplanin (PDPN), a small transmembrane mucin-like glycoprotein, is ectopically expressed on tumor cells. PDPN is known to be linked with several aspects of tumor malignancies in certain types of human and canine tumors. Therefore, it is considered to be a novel therapeutic target. Monoclonal antibodies targeting PDPN expressed in human tumor cells showed obvious anti-tumor effects in preclinical studies using mouse models. Previously, we generated a cancer-specific mouse–dog chimeric anti-PDPN antibody, P38Bf, which specifically recognizes PDPN expressed in canine tumor cells. In this study, we investigated the safety and anti-tumor effects of P38Bf in preclinical and clinical trials. P38Bf showed dose-dependent antibody-dependent cellular cytotoxicity against canine malignant melanoma cells. In a preclinical trial with one healthy dog, P38Bf administration did not induce adverse effects over approximately 2 months. In phase I/II clinical trials of three dogs with malignant melanoma, one dog vomited, and all dogs had increased serum levels of C-reactive protein, although all adverse effects were grade 1 or 2. Severe adverse effects leading to withdrawal of the clinical trial were not observed. Furthermore, one dog had stable disease with P38Bf injections. This is the first reported clinical trial of anti-PDPN antibody therapy using spontaneously occurring canine tumor models.

show abstract

“…A recent review of the failures of some investigational ADCs, as well as the suspension of a few programs, points to technical hurdles encountered during the development of this type of product, and provides a view on the issues that might affect the design and development of nextgeneration ADCs for the treatment of ErbB2-expressing tumors. 50…”

Section: Alternative/improved T-dm1mentioning

confidence: 99%

Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy

Santis

2020

mAbs

View full text Add to dashboard Cite

Over the past 3 decades, monoclonal antibodies and their related derivatives, including recently approved antibody-drug conjugates, conquered a central role in cancer therapy because of their contribution to improve survival, time to progression and quality of life of patients compared to chemotherapy protocols. This review summarizes information on approved original and biosimilar products, as well as investigational antibody-based therapeutics, targeting ErbB2. This target has been selected as a paradigmatic example because of its relevant role in sustaining the malignancy of major cancer diseases including, breast, gastric and other chemotherapy-resistant solid tumors. This work analyzes the drivers affecting research and development of next-generation anti-ErbB2 immunotherapeutics, taking into account unmet medical needs and pharmacoeconomic issues related to sustainability. The analysis may help with the design of future research and development strategies.

show abstract

Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review

Cited by 66 publications

References 79 publications

Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis

Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis

Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma

Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy

Contact Info

Product

Resources

About